- Biogen Idec's (NASDAQ:BIIB) Eloctate long-lasting treatment for Haemophilia A, which the company is developing with Swedish Orphan Biovitrum (Sobi), maintained low bleeding rates in children under the age of 12 in a Phase III study.
- The results enable submission for EU approval. (PR)
- Separately, Biogen has named Ada Koppel as Chief Strategy Officer. Koppel comes from Brookside Capital, the public-equity affiliate of Bain Capital. (PR)